Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, akawanda myeloma
KITE NEARCELLX VHARA CHIBVIRIRO CHEKUBVA-KUDZIDZA UYE CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD GUTA, Calif.-- (BUSINESS WIRE)-- Kite, Kambani yeGiriyedhi (NASDAQ: GILD), uye Arcellx, Inc. (NASDAQ: ACLX), nhasi yakazivisa kuvharwa kwemakambani kare. yakazivisa global Strategic..
bhora, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel inotenderwa neFDA kuti idzoke kana refractory B-cell precursor acute lymphoblastic leukemia.
Gumiguru 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) yakabvumidzwa neFood and Drug Administration yevarwere vakuru vane kudzoka kana kuramba B-cell precursor acute lymphoblastic leukemia (ALL). Mu..
axicabtagene ciloleucel, MOTO - T Cell kurapwa, CD19, follicular lymphoma, Kite Pharma, inoratidzira follicular lymphoma, yakadzokazve follicular lymphoma, Yescarta
Iyo FDA yakapa axicabtagene ciloleucel yakamhanyisa mvumo yekudzokazve kana kusagadzikana follicular lymphoma.
Nyamavhuvhu 2021: Iyo FDA yakapa axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) mvumo yekuchimbidza kuvarwere vakuru vane kudzokazve kana refractory follicular lymphoma (FL) mushure memitsara miviri kana kupfuura yesystemic therapy. Kuimba..